LONDON (Alliance News) - Shares in ValiRx PLC rose 8% Tuesday after it saw positive first results from a phase I/II clinical trial of its VAL201 compound in patients with cancer.
The company said that VAL201 was safe and well tolerated at the doses tested. It will now advance the trial to the next elevation of dose for further safety and tolerability testing, as well as early stage efficacy testing. The trial is intended to gather data on the maximum applicable dose level possible.
"This first result from the clinical trial of the ValiRx compound VAL201 demonstrates a good safety profile and I am pleased to see the study successfully progressing well," said Chief Executive OFficer Satu Vainikka in a statement.
Shares in ValiRX are trading up 8% at 0.270 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
ValiRx (VAL)